Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12 month, partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody, CFZ533, in de novo and maintenance kidney transplant recipients (CIRRUS I)

Trial Profile

A 12 month, partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody, CFZ533, in de novo and maintenance kidney transplant recipients (CIRRUS I)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs CFZ 533 (Primary) ; CFZ 533 (Primary) ; Mycophenolate mofetil; Prednisolone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms CIRRUS I
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 30 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top